- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05990621
Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms
A Single-arm, Open-label, Dose-escalation/Expansion, Early-phase Clinical Study of Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urological Neoplasms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will include two parts, dose escalation phase (accelerated titration and 3+3 design) followed by a dose expansion phase. All eligible participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by CAR-T cell injection.
The dose escalation phase will determine the maximum tolerated dose (MTD) of Anti-CD70 CAR-T cell injection. Additional patients will be enrolled in the dose expansion phase to further characterize the safety profile and evaluate the efficacy of Anti-CD70 CAR-T cell injection, and establish recommended phase 2 dose (RP2D).
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Yewei Bao
- Phone Number: 13612400566
- Email: 16ywbao@alumni.stu.edu.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recruiting
- Changhai Hospital
-
Contact:
- Yewei Bao
- Phone Number: 13612400566
- Email: 16ywbao@alumni.stu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Subject is≥18 years old (including cut-off value), gender is not limited. 2. Histopathologically confirmed tumors of the urinary system (including renal cancers and urothelial cancers). Renal cancers should have failed after targeted therapy and/or immunotherapy. Urothelial cancers should have failed after chemotherapy and/or immunotherapy. Or subjects are unable to tolerate or lack effective therapies.
3. At least one measurable lesion according to RECIST v1.1. 4. CD70 should be positive confirmed by Immunohistochemistry/Immunocytochemistry/ Flow Cytometry (IHC/ICC/FCM) in tumor tissue samples.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy ≥ 3 months. 7. Adequate function defined as: Hematological functions: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L (Patients should not receive G-CSF support within 7 days before laboratory examination); Absolute Lymphocyte Count (ALC) ≥ 0.5 × 109/L; Hemoglobin (HGB) ≥ 80 g/L (Patients should not be transfused red cells within 7 days before the laboratory examination); Platelet count (PLT) ≥ 75 × 109/L (Patients should not receive transfusion support within 7 days before the laboratory examination).
Hepatic functions: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN); AST and ALT of patients with liver metastasis ≤ 5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; TBIL of patients with liver metastasis must ≤ 3.0 × ULN; TBIL of patients with Gilbert's Syndrome ≤ 3.0 × ULN and Direct bilirubin (DBIL) ≤ 1.5 × ULN.
Coagulation functions: International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (Except for patients who are receiving therapeutic anticoagulants.).
Renal functions: Serum creatinine (Cr) ≤ 1.5 × ULN; or Estimated glomerular filtration rate (eGFR) ≥30ml/(min·1.73 m2)(Calculated by CKD⁃EPI).
Cardiac functions: Left ventricular ejection fraction (LVEF) > 50%; Pulmonary function: Oxygen saturation (SpO2) > 92%. 8. Female participants of childbearing potential must undergo a pregnancy test and the results must be negative. Female participants of childbearing potential or male participants whose sex partner has childbearing potential must be willing to use effective methods of contraception from screening period to at least 1 year after infusion.
9. Participants must be able to understand the protocol and be willing to enroll the study, sign the informed consent, and be able to comply with the study and follow-up procedures.
Exclusion Criteria:
1. Patients have received systemic therapy with cytotoxic chemicals, monoclonal antibodies, or immunotherapy within 4 weeks or 5 half-lives (which is shorter) prior to signing informed consent; Patients have received systemic glucocorticoids (prednisone at a dose of ≥10 mg per day or equivalent) or other immune-suppressive therapy within 2 weeks prior to signing informed consent; Patients have received systemic antitumor therapy with a biologic agent or other approved targeted small-molecule inhibitor within 1 week or five half-lives (which is shorter) prior to signing informed consent; Patients have received Chinese herbal medicine or Chinese patent medicine with anti-tumor indication within 1 week prior to signing informed consent.
2. Pregnant or lactating women. 3. Patients with hepatitis B surface antigen (HBsAg) positive. Patients who is hepatitis B core antibody (HBcAb) positive and the quantification of HBV DNA in peripheral blood is higher than the lower limit of detection. Patients who is hepatitis C virus (HCV) antibody positive and quantification of HCV DNA in peripheral blood is higher than the lower limit of detection. Patients with human immunodeficiency virus (HIV) antibody positive. Patients with syphilis antibody positive and tolulized red unheated serum test (TRUST) titer ≥ 1:4.
4. The toxicities caused by the prior therapy (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) have not recovered to grade 1 according to CTCAE, except for hair loss and peripheral sensory nerve disorders.
5. Have received any allogeneic tissue/organ transplantation (including bone marrow transplantation, stem cell transplantation, liver transplantation, kidney transplantation), except for the transplantation that does not require immunosuppressive therapy (such as: corneal transplantation, hair transplantation.) 6. Patients have received anti-CD70 CAR-T cell therapy. 7. Patients who have history of major surgery and unrecovered severe trauma within 4 weeks prior to signing informed consent; or plan to have major surgery within 12 weeks of cell therapy.
8. Presence of known central nervous system metastases, but the following patients will be allowed: a) Asymptomatic brain metastases; b) Clinically stable (no radiographic progression within 4 weeks before apheresis and return of any neurologic symptoms to baseline), and with no need for corticosteroids or other treatment for brain metastases for ≥ 4 weeks.
9. Patients with clinically significant systemic disease (such as: severe active infection or significant cardiac, pulmonary, hepatic, nervous system, or other organ dysfunction) that evaluated by the investigator would impair the patients' ability to tolerate the treatments used in this study or significantly increase the risk of complications.
- Uncontrolled severe active infection (sepsis, bacteremia, viremia, etc.);
- Congestive heart failure with New York Heart Association (NYHA) functional class > 1;
- Clinically significant severe aortic stenosis and symptomatic mitral stenosis;
- Electrocardiogram QTc > 450 msec or QTc > 480 msec in patients with bundle-branch block;
- Uncontrolled clinically significant arrhythmia within 6 months prior to signing informed consent;
- Acute coronary syndrome (such as: unstable angina, myocardial infarction) within 6 months prior to signing informed consent;
- Drug-uncontrolled hypertension (systolic pressure ≥ 160 mmHg and/or diastolic pressure ≥ 100 mmHg) or pulmonary hypertension;
- Cerebrovascular accident occurred within 6 months prior to signing informed consent, including transient ischemic attack (TIA), cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage;
A history of active, chronic, or recurrent (within 1 year prior to signing informed consent) severe autoimmune disease or immune-mediated disease requiring steroids or other immunosuppressive therapy, including but not limited to systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis, autoimmune thyroid disease, multiple sclerosis. Exceptions: hypothyroidism that can be controlled only by hormone replacement therapy, skin diseases (such as: vitiligo, psoriasis) that do not require systemic treatment, coeliac disease that has been controlled; 10. Any form of primary or secondary immunodeficiency, such as severe combined immunodeficiency (SCID); 11. History of severe systemic hypersensitivity reaction to the drugs/ingredients [fludarabine, cyclophosphamide, dimethyl sulfoxide (DMSO), low molecular dextran, human serum albumin (HSA), etc.] used in this study.
12. Patients have received attenuated vaccine within 4 weeks prior to signing informed consent.
13. Patients have received other clinical trials within 4 weeks prior to signing informed consent.
14. History of another malignancy tumor within the previous five years, except for adequately treated non-melanoma skin cancer, carcinoma in situ of bladder, stomach, colon, cervix/dysplasia, melanoma, or breast.
15. History of neuropsychiatric diseases diagnosed by the ICD-11 criteria or evaluated by investigator, including but not limited to epilepsy, schizophrenia, dementia, drug and alcohol addictions.
16. For any other reasons, the patients are believed not suitable for participation in this study by investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anti-CD70 CAR-T cells
Anti-CD70 CAR-T cells are autologous genetically modified T cells.
|
0.6×106/Kg ~ 5.0×106/Kg; cells will be infused intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: 2 years
|
Incidence and severity of adverse events.
|
2 years
|
Serious Adverse Events (SAEs)
Time Frame: 2 years
|
Incidence and severity of serious adverse events.
|
2 years
|
Adverse Events of Special Interest (AESI)
Time Frame: 2 years
|
Incidence and severity of adverse event of special interest.
|
2 years
|
Identification of Maximum Tolerated Dose (MTD)
Time Frame: 4 weeks after the CAR-T cells infusion
|
Incidence and severity of dose-limiting toxicities (DLTs) following infusion of UCL70802 cell injection, at each dose level tested in dose escalation phase.
|
4 weeks after the CAR-T cells infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: 2 years
|
The Objective Response Rate (ORR) is the percentage of participants who achieved Complete Response (CR) or Partial Response (PR) based on RECIST version 1.1.
|
2 years
|
Duration of Overall Response (DOR)
Time Frame: 2 years
|
Time from documentation of disease response to disease progression.
|
2 years
|
Progression-Free Survival (PFS)
Time Frame: 2 years
|
PFS is defined as the time from CAR-T infusion to the date of the disease progression or death from any cause.
|
2 years
|
Overall Survival (OS)
Time Frame: 2 years
|
OS is defined as the time from CAR-T infusion to the date of death due to any cause.
|
2 years
|
Bio-distribution of Anti-CD70 CAR-T cells
Time Frame: 2 years
|
CAR copies will be measured by qPCR to evaluate the expansion and persistence of CAR-T cells in vivo.
|
2 years
|
Cytokine Level in Peripheral Blood
Time Frame: 2 years
|
Level of cytokines (IFN-γ, IL-6, IL-2, etc.) in serum.
|
2 years
|
Number of participants with anti-drug antibodies.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Linhui Wang, Changhai Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Anti-CD70 CAR-T Cell Injection
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CD70-positive Advanced Urologic Neoplasms
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Not yet recruitingCldn18.2-positive Advanced Solid TumorChina
-
Chinese PLA General HospitalUnknownAdvanced EGFR-positive Solid TumorsChina
-
Chinese PLA General HospitalFudan UniversityRecruitingHER2 Positive Advanced Solid TumorsChina
-
Shanghai Pharmaceuticals Holding Co., LtdRecruitingHER2-positive Advanced Solid TumorsChina
-
Changchun Intellicrown Pharmaceutical Co. LTDCovanceRecruitingAdvanced EGFR Positive Solid TumorUnited States, China
-
Samsung Medical CenterCompletedHER2-positive Refractory Advanced CancerKorea, Republic of
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingHER2-positive Advanced Solid TumorsChina
-
Hangzhou Adcoris Biopharmacy Co., LtdEnrolling by invitationHER2-positive Advanced Solid TumorChina
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
D3 Bio (Wuxi) Co., LtdRecruitingHER-2 Positive Advanced Solid TumorsUnited States, China
Clinical Trials on Anti-CD70 CAR-T cells
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAcute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's LymphomaChina
-
Weijia Fang, MDChongqing Precision Biotech Co., LtdRecruitingRenal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic TumorChina
-
Chongqing Precision Biotech Co., LtdRecruitingRenal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic TumorChina
-
Chongqing Precision Biotech Co., LtdRecruitingRenal Cell Carcinoma | Advanced Cancer | Metastatic TumorChina
-
Chongqing Precision Biotech Co., LtdRecruitingGynecologic Cancer | Ovarian Cancer | Metastatic Cancer | Cervix Cancer | Advanced CancerChina
-
Chongqing Precision Biotech Co., LtdThe First Affiliated Hospital of Nanchang UniversityRecruitingRenal Cell Carcinoma | Ovarian Cancer | Metastatic Cancer | Cervix Cancer | Advanced CancerChina
-
Chongqing Precision Biotech Co., LtdRecruitingRenal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic TumorChina
-
Chinese PLA General HospitalUTC Therapeutics Inc.RecruitingSolid Tumor, AdultChina
-
Chinese PLA General HospitalUTC Therapeutics Inc.Recruiting
-
Shenzhen Geno-Immune Medical InstituteRecruiting